Wegovy Slashes Heavy Drinking Days by 41% in Landmark Alcohol Use Disorder Trial
A Danish RCT finds semaglutide dramatically reduces heavy drinking days and cravings in adults with obesity and alcohol use disorder.
Summary
A randomized controlled trial published in The Lancet found that semaglutide (Wegovy), the GLP-1 receptor agonist widely used for weight loss, significantly reduced heavy drinking days in adults with obesity and alcohol use disorder. Over 26 weeks, participants on semaglutide saw a 41% reduction in heavy drinking days compared to 26% for placebo. Beyond drinking frequency, semaglutide also lowered overall alcohol consumption, reduced craving scores, and improved liver health biomarkers. Researchers say the effect size rivals or exceeds existing FDA-approved alcohol use disorder medications, which are already vastly underused. The findings support growing interest in GLP-1 drugs as potential treatments for addiction, though experts caution that off-label prescribing is outpacing the evidence base.
Detailed Summary
Alcohol use disorder affects tens of millions of people worldwide, yet existing FDA-approved treatments are rarely prescribed and offer only modest benefits. A new randomized controlled trial published in The Lancet suggests semaglutide, the active ingredient in Wegovy, could meaningfully change that picture by targeting both the metabolic and neurological drivers of addictive behavior.
The Danish trial enrolled adults with both obesity and alcohol use disorder, all of whom also received cognitive behavioral therapy. After 26 weeks, those on a 2.4 mg weekly dose of semaglutide experienced a 41.1 percentage point reduction in heavy drinking days, compared to 26.4 percentage points in the placebo group — a statistically significant difference. Secondary outcomes were equally encouraging: semaglutide users showed lower overall alcohol consumption, reduced craving scores, and improved biological markers of liver health.
The researchers and accompanying commentators note that this effect size is clinically meaningful when benchmarked against existing options like naltrexone, acamprosate, and disulfiram — all of which show only small to moderate effects in trials and remain vastly underutilized in practice. NIH's National Institute on Alcohol Abuse and Alcoholism director George Koob called a more accessible, more effective option a potential game-changer for closing the treatment gap.
This trial is the first to test semaglutide in treatment-seeking patients with alcohol use disorder, adding critical real-world validity to earlier lab-based findings. It also arrives amid a surge of off-label GLP-1 prescribing for addiction, which experts warn is currently ahead of the evidence. Seven additional GLP-1 and metabolic agents are now under investigation for alcohol-related conditions.
For health-conscious adults, the findings reinforce that GLP-1 drugs may have broad benefits beyond weight and blood sugar — but clinical guidance should precede use for addiction. Larger and longer trials are needed before semaglutide becomes a standard-of-care option for alcohol use disorder.
Key Findings
- Semaglutide reduced heavy drinking days by 41% vs 26% for placebo over 26 weeks in a randomized trial.
- GLP-1 treatment also lowered total alcohol consumption, craving scores, and improved liver health biomarkers.
- Effect size rivals or exceeds existing FDA-approved alcohol use disorder medications like naltrexone.
- This is the first RCT testing semaglutide in treatment-seeking alcohol use disorder patients, boosting real-world relevance.
- Seven additional GLP-1 drugs are now under investigation for alcohol use disorder or alcohol-related liver disease.
Methodology
This is a news report summarizing a peer-reviewed randomized placebo-controlled trial published in The Lancet, a high-credibility medical journal. The source, MedPage Today, is a reputable clinical news outlet. The trial included a 26-week follow-up with a clinically relevant primary endpoint and multiple secondary outcomes.
Study Limitations
The article is a news summary and does not provide full trial details such as sample size, dropout rates, or adverse event profiles. The study population was limited to adults with both obesity and alcohol use disorder, limiting generalizability to lean individuals or those with alcohol use disorder alone. Primary source review of the full Lancet publication is recommended before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.